false2024Q3000177191012/31110.6904109589041116.69041095890411P2Yxbrli:sharesiso4217:USDiso4217:CHFxbrli:sharesiso4217:USDxbrli:sharesadc:subsidiaryadc:segmentxbrli:pure00017719102024-01-012024-09-3000017719102024-11-0100017719102024-09-3000017719102023-12-3100017719102024-07-012024-09-3000017719102023-07-012023-09-3000017719102023-01-012023-09-300001771910us-gaap:CommonStockMember2024-06-300001771910us-gaap:AdditionalPaidInCapitalMember2024-06-300001771910us-gaap:TreasuryStockCommonMember2024-06-300001771910us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001771910us-gaap:RetainedEarningsMember2024-06-3000017719102024-06-300001771910us-gaap:RetainedEarningsMember2024-07-012024-09-300001771910us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001771910us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001771910us-gaap:TreasuryStockCommonMember2024-07-012024-09-300001771910us-gaap:CommonStockMember2024-07-012024-09-300001771910us-gaap:CommonStockMember2024-09-300001771910us-gaap:AdditionalPaidInCapitalMember2024-09-300001771910us-gaap:TreasuryStockCommonMember2024-09-300001771910us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001771910us-gaap:RetainedEarningsMember2024-09-300001771910us-gaap:CommonStockMember2023-12-310001771910us-gaap:AdditionalPaidInCapitalMember2023-12-310001771910us-gaap:TreasuryStockCommonMember2023-12-310001771910us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001771910us-gaap:RetainedEarningsMember2023-12-310001771910us-gaap:RetainedEarningsMember2024-01-012024-09-300001771910us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300001771910us-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-300001771910us-gaap:TreasuryStockCommonMember2024-01-012024-09-300001771910us-gaap:CommonStockMember2024-01-012024-09-300001771910us-gaap:CommonStockMember2023-06-300001771910us-gaap:AdditionalPaidInCapitalMember2023-06-300001771910us-gaap:TreasuryStockCommonMember2023-06-300001771910us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001771910us-gaap:RetainedEarningsMember2023-06-3000017719102023-06-300001771910us-gaap:RetainedEarningsMember2023-07-012023-09-300001771910us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001771910us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001771910us-gaap:TreasuryStockCommonMember2023-07-012023-09-300001771910us-gaap:CommonStockMember2023-09-300001771910us-gaap:AdditionalPaidInCapitalMember2023-09-300001771910us-gaap:TreasuryStockCommonMember2023-09-300001771910us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001771910us-gaap:RetainedEarningsMember2023-09-3000017719102023-09-300001771910us-gaap:CommonStockMember2022-12-310001771910us-gaap:AdditionalPaidInCapitalMember2022-12-310001771910us-gaap:TreasuryStockCommonMember2022-12-310001771910us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001771910us-gaap:RetainedEarningsMember2022-12-3100017719102022-12-310001771910us-gaap:RetainedEarningsMember2023-01-012023-09-300001771910us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300001771910us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300001771910us-gaap:TreasuryStockCommonMember2023-01-012023-09-300001771910us-gaap:CommonStockMember2023-01-012023-09-300001771910us-gaap:FairValueInputsLevel1Member2024-09-300001771910us-gaap:FairValueInputsLevel2Member2024-09-300001771910adc:DeerfieldWarrantsMember2024-09-300001771910us-gaap:FairValueInputsLevel3Member2024-09-300001771910us-gaap:FairValueInputsLevel1Member2023-12-310001771910us-gaap:FairValueInputsLevel2Member2023-12-310001771910us-gaap:FairValueInputsLevel3Member2023-12-310001771910us-gaap:LeaseholdImprovementsMember2024-09-300001771910us-gaap:LeaseholdImprovementsMember2023-12-310001771910adc:LaboratoryEquipmentMember2024-09-300001771910adc:LaboratoryEquipmentMember2023-12-310001771910us-gaap:OfficeEquipmentMember2024-09-300001771910us-gaap:OfficeEquipmentMember2023-12-310001771910adc:HardwareAndSoftwareMember2024-09-300001771910adc:HardwareAndSoftwareMember2023-12-310001771910adc:OverlandADCTBioPharmaCYLimitedMember2022-12-310001771910adc:OverlandADCTBioPharmaCYLimitedMember2023-01-012023-12-310001771910adc:OverlandADCTBioPharmaCYLimitedMember2023-12-310001771910adc:OverlandADCTBioPharmaCYLimitedMember2024-01-012024-09-300001771910adc:OverlandADCTBioPharmaCYLimitedMember2024-09-300001771910us-gaap:SecuredDebtMemberadc:LoanAgreementMemberus-gaap:LineOfCreditMember2022-08-150001771910us-gaap:SecuredDebtMemberadc:LoanAgreementMemberus-gaap:LineOfCreditMember2022-08-152022-08-150001771910adc:LoanAgreementWarrantsMember2022-08-1500017719102022-08-152022-08-150001771910adc:LoanAgreementMember2024-07-012024-09-300001771910adc:LoanAgreementMember2024-01-012024-09-300001771910adc:LoanAgreementMember2023-07-012023-09-300001771910adc:LoanAgreementMember2023-01-012023-09-300001771910us-gaap:SecuredDebtMemberadc:LoanAgreementMemberus-gaap:LineOfCreditMember2024-09-300001771910us-gaap:SecuredDebtMemberadc:LoanAgreementMemberus-gaap:LineOfCreditMember2024-07-012024-09-300001771910us-gaap:SecuredDebtMemberadc:LoanAgreementMemberus-gaap:LineOfCreditMember2023-07-012023-09-300001771910us-gaap:SecuredDebtMemberadc:LoanAgreementMemberus-gaap:LineOfCreditMember2024-01-012024-09-300001771910us-gaap:SecuredDebtMemberadc:LoanAgreementMemberus-gaap:LineOfCreditMember2023-01-012023-09-300001771910adc:LoanAgreementMember2024-09-300001771910adc:DeerfieldWarrantsMember2022-08-152022-08-150001771910adc:WarrantsTrancheOneMemberadc:DeerfieldWarrantsMember2022-08-152022-08-150001771910adc:WarrantsTrancheOneMemberadc:DeerfieldWarrantsMember2022-08-150001771910adc:WarrantsTrancheTwoMemberadc:DeerfieldWarrantsMember2022-08-152022-08-150001771910adc:WarrantsTrancheTwoMemberadc:DeerfieldWarrantsMember2022-08-150001771910adc:DeerfieldWarrantsMember2024-07-012024-09-300001771910adc:DeerfieldWarrantsMember2024-01-012024-09-300001771910adc:DeerfieldWarrantsMember2023-07-012023-09-300001771910adc:DeerfieldWarrantsMember2023-01-012023-09-300001771910adc:DeerfieldWarrantsMember2023-12-310001771910adc:DeerfieldWarrantsMemberus-gaap:MeasurementInputExercisePriceMembersrt:MinimumMember2024-09-300001771910adc:DeerfieldWarrantsMemberus-gaap:MeasurementInputExercisePriceMembersrt:MaximumMember2024-09-300001771910adc:DeerfieldWarrantsMemberus-gaap:MeasurementInputExercisePriceMembersrt:MinimumMember2023-12-310001771910adc:DeerfieldWarrantsMemberus-gaap:MeasurementInputExercisePriceMembersrt:MaximumMember2023-12-310001771910adc:DeerfieldWarrantsMemberus-gaap:MeasurementInputSharePriceMember2024-09-300001771910adc:DeerfieldWarrantsMemberus-gaap:MeasurementInputSharePriceMember2023-12-310001771910adc:DeerfieldWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2024-09-300001771910adc:DeerfieldWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2023-12-310001771910adc:DeerfieldWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2024-09-300001771910adc:DeerfieldWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2023-12-310001771910adc:DeerfieldWarrantsMemberadc:MeasurementInputDividendYieldMember2024-09-300001771910adc:DeerfieldWarrantsMemberadc:MeasurementInputDividendYieldMember2023-12-310001771910adc:DeerfieldWarrantsMemberadc:MeasurementInputValueMembersrt:MinimumMember2024-09-300001771910adc:DeerfieldWarrantsMemberadc:MeasurementInputValueMembersrt:MaximumMember2024-09-300001771910adc:DeerfieldWarrantsMemberadc:MeasurementInputValueMembersrt:MinimumMember2023-12-310001771910adc:DeerfieldWarrantsMemberadc:MeasurementInputValueMembersrt:MaximumMember2023-12-310001771910adc:DeerfieldWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2024-09-300001771910adc:DeerfieldWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2023-12-3100017719102021-08-252021-08-2500017719102023-01-012023-12-310001771910adc:A2024EquityOfferingMember2024-05-012024-05-310001771910us-gaap:CommonStockMemberadc:A2024EquityOfferingMember2024-05-310001771910adc:A2024PreFundedWarrantMemberadc:A2024EquityOfferingMember2024-05-012024-05-310001771910adc:A2024EquityOfferingMember2024-05-3100017719102024-05-310001771910adc:A2024PreFundedWarrantMember2024-05-310001771910srt:MinimumMemberadc:A2024PreFundedWarrantMember2024-05-012024-05-310001771910srt:MaximumMemberadc:A2024PreFundedWarrantMember2024-05-012024-05-310001771910adc:A2024PreFundedWarrantMember2024-05-012024-05-310001771910adc:PublicStockOfferingMember2023-01-012023-09-300001771910us-gaap:ProductMember2024-07-012024-09-300001771910us-gaap:ProductMember2023-07-012023-09-300001771910us-gaap:ProductMember2023-01-012023-09-300001771910adc:RoyaltyRevenueMember2024-07-012024-09-300001771910adc:RoyaltyRevenueMember2023-07-012023-09-300001771910adc:RoyaltyRevenueMember2023-01-012023-09-300001771910country:US2024-07-012024-09-300001771910country:US2023-07-012023-09-300001771910country:US2024-01-012024-09-300001771910country:US2023-01-012023-09-300001771910us-gaap:EMEAMember2024-07-012024-09-300001771910us-gaap:EMEAMember2023-07-012023-09-300001771910us-gaap:EMEAMember2024-01-012024-09-300001771910us-gaap:EMEAMember2023-01-012023-09-300001771910adc:DiscardedDrugRebateMember2024-06-300001771910adc:OtherAdjustmentsMember2024-06-300001771910adc:DiscardedDrugRebateMember2024-07-012024-09-300001771910adc:OtherAdjustmentsMember2024-07-012024-09-300001771910adc:DiscardedDrugRebateMember2024-09-300001771910adc:OtherAdjustmentsMember2024-09-300001771910adc:DiscardedDrugRebateMember2023-12-310001771910adc:OtherAdjustmentsMember2023-12-310001771910adc:DiscardedDrugRebateMember2024-01-012024-09-300001771910adc:OtherAdjustmentsMember2024-01-012024-09-300001771910adc:DiscardedDrugRebateMember2023-06-300001771910adc:OtherAdjustmentsMember2023-06-300001771910adc:DiscardedDrugRebateMember2023-07-012023-09-300001771910adc:OtherAdjustmentsMember2023-07-012023-09-300001771910adc:DiscardedDrugRebateMember2023-09-300001771910adc:OtherAdjustmentsMember2023-09-300001771910adc:DiscardedDrugRebateMember2022-12-310001771910adc:OtherAdjustmentsMember2022-12-310001771910adc:DiscardedDrugRebateMember2023-01-012023-09-300001771910adc:OtherAdjustmentsMember2023-01-012023-09-300001771910us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberadc:McKessonMember2024-07-012024-09-300001771910us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberadc:McKessonMember2023-07-012023-09-300001771910us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberadc:McKessonMember2024-01-012024-09-300001771910us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberadc:McKessonMember2023-01-012023-09-300001771910us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberadc:AmerisourceBergenCorporationMember2024-07-012024-09-300001771910us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberadc:AmerisourceBergenCorporationMember2023-07-012023-09-300001771910us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberadc:AmerisourceBergenCorporationMember2024-01-012024-09-300001771910us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberadc:AmerisourceBergenCorporationMember2023-01-012023-09-300001771910us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberadc:CardinalHealthMember2024-07-012024-09-300001771910us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberadc:CardinalHealthMember2023-07-012023-09-300001771910us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberadc:CardinalHealthMember2024-01-012024-09-300001771910us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberadc:CardinalHealthMember2023-01-012023-09-300001771910adc:A2019EquityIncentivePlanMember2019-11-300001771910us-gaap:StockCompensationPlanMemberadc:A2019EquityIncentivePlanMember2024-09-300001771910adc:A2019EquityIncentivePlanMember2024-01-012024-09-300001771910adc:A2019EquityIncentivePlanMember2023-01-012023-12-310001771910adc:A2019EquityIncentivePlanMember2024-07-012024-09-300001771910adc:A2019EquityIncentivePlanMember2023-07-012023-09-300001771910adc:A2019EquityIncentivePlanMember2023-01-012023-09-300001771910adc:ConditionalShareCapitalPlanMember2023-12-310001771910adc:ConditionalShareCapitalPlanMember2024-09-300001771910adc:ConditionalShareCapitalPlanMember2024-01-012024-09-300001771910adc:ConditionalShareCapitalPlanMember2024-07-012024-09-300001771910adc:InducementPlanMember2023-12-310001771910adc:InducementPlanMember2024-09-300001771910adc:InducementPlanMember2024-01-012024-09-300001771910adc:InducementPlanMember2024-07-012024-09-300001771910us-gaap:EmployeeStockOptionMember2019-11-012019-11-300001771910us-gaap:StockCompensationPlanMember2024-07-012024-09-300001771910us-gaap:StockCompensationPlanMember2024-01-012024-09-300001771910us-gaap:StockCompensationPlanMember2023-07-012023-09-300001771910us-gaap:StockCompensationPlanMember2023-01-012023-09-300001771910us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001771910srt:MinimumMemberus-gaap:EmployeeStockOptionMember2024-07-012024-09-300001771910srt:MaximumMemberus-gaap:EmployeeStockOptionMember2024-07-012024-09-300001771910srt:MinimumMemberus-gaap:EmployeeStockOptionMember2023-07-012023-09-300001771910srt:MaximumMemberus-gaap:EmployeeStockOptionMember2023-07-012023-09-300001771910srt:MinimumMemberus-gaap:EmployeeStockOptionMember2024-01-012024-09-300001771910srt:MaximumMemberus-gaap:EmployeeStockOptionMember2024-01-012024-09-300001771910srt:MinimumMemberus-gaap:EmployeeStockOptionMember2023-01-012023-09-300001771910srt:MaximumMemberus-gaap:EmployeeStockOptionMember2023-01-012023-09-300001771910us-gaap:EmployeeStockOptionMember2024-07-012024-09-300001771910us-gaap:EmployeeStockOptionMember2023-07-012023-09-300001771910us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001771910srt:MinimumMemberus-gaap:RestrictedStockUnitsRSUMemberadc:A2019EquityIncentivePlanMember2019-11-012019-11-300001771910srt:MaximumMemberus-gaap:RestrictedStockUnitsRSUMemberadc:A2019EquityIncentivePlanMember2019-11-012019-11-300001771910us-gaap:RestrictedStockUnitsRSUMemberadc:A2019EquityIncentivePlanMember2024-07-012024-09-300001771910us-gaap:RestrictedStockUnitsRSUMemberadc:A2019EquityIncentivePlanMember2024-01-012024-09-300001771910us-gaap:RestrictedStockUnitsRSUMemberadc:A2019EquityIncentivePlanMember2023-07-012023-09-300001771910us-gaap:RestrictedStockUnitsRSUMemberadc:A2019EquityIncentivePlanMember2023-01-012023-09-300001771910us-gaap:RestrictedStockUnitsRSUMember2023-12-310001771910us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001771910us-gaap:RestrictedStockUnitsRSUMember2024-09-300001771910us-gaap:RestrictedStockUnitsRSUMemberadc:ConditionalShareCapitalPlanMember2024-09-300001771910us-gaap:EmployeeStockMemberadc:A2022EmployeeStockPurchasePlanMember2022-06-012022-06-300001771910adc:A2022EmployeeStockPurchasePlanMember2024-07-012024-09-300001771910adc:A2022EmployeeStockPurchasePlanMember2024-01-012024-09-300001771910adc:A2022EmployeeStockPurchasePlanMember2023-07-012023-09-300001771910adc:A2022EmployeeStockPurchasePlanMember2023-01-012023-09-300001771910adc:A2019EquityIncentivePlanMemberus-gaap:EmployeeStockOptionMember2024-01-012024-09-300001771910adc:A2019EquityIncentivePlanMemberus-gaap:EmployeeStockOptionMember2023-01-012023-09-300001771910adc:InducementPlanMember2024-01-012024-09-300001771910adc:InducementPlanMember2023-01-012023-09-300001771910adc:A2019EquityIncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001771910adc:A2019EquityIncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001771910adc:ConditionalShareCapitalPlanMember2024-01-012024-09-300001771910adc:ConditionalShareCapitalPlanMember2023-01-012023-09-300001771910us-gaap:WarrantMember2024-01-012024-09-300001771910us-gaap:WarrantMember2023-01-012023-09-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

(Mark One)

Commission File Number: 001-39071

ADC Therapeutics SA
(Exact name of registrant as specified in its charter)

(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒          No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒          No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐          No ☒

The number of common shares outstanding was 96,689,617 as of November 1, 2024.

Unless otherwise indicated or the context otherwise requires, all references in this Annual Report to “ADC Therapeutics,” “ADCT,” the “Company,” “we,” “our,” “ours,” “us” or similar terms refer to ADC Therapeutics SA and its consolidated subsidiaries.

This Quarterly Report contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding our future catalysts, results of operations and financial position, business and commercial strategy, market opportunities, products and product candidates, research pipeline, ongoing and planned preclinical studies and clinical trials, regulatory submissions and approvals, research and development costs, projected revenues and expenses and the timing of revenues and expenses, timing and likelihood of success, as well as plans and objectives of management for future operations are forward-looking statements. Many of the forward-looking statements contained in this Quarterly Report can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “estimate,” “will” and “potential,” among others.

Forward-looking statements are based on our management’s beliefs and assumptions and on information available to our management at the time such statements are made. Such statements are subject to known and unknown risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to:

•the substantial net losses that we have incurred since our inception, our expectation to continue to incur losses for the foreseeable future and our need to raise additional capital to fund our operations and execute our business plan;

•our indebtedness under the loan agreement and guaranty (the “Loan Agreement”) with certain affiliates and/or funds managed by each of Oaktree Capital Management, L.P. and Owl Rock Capital Advisors LLC, as lenders, and Blue Owl Opportunistic Master Fund I, L.P., as administrative agent, and the associated restrictive covenants thereunder;

•the purchase and sale agreement (the “HCR Agreement”) with certain entities managed by HealthCare Royalty Management, LLC (“HCR”) and its negative effect on the amount of cash that we are able to generate from sales of, and licensing agreements involving, ZYNLONTA and on our attractiveness as an acquisition target;

•our ability to complete clinical trials on expected timelines, if at all;

•the timing, outcome and results of ongoing or planned clinical trials, whether the Company sponsored trials or through investigator initiated trials, and the sufficiency of such results;

•undesirable side effects or adverse events of our products and product candidates;

•our and our partners’ ability to obtain and maintain regulatory approval for our product and product candidates;

•our and our partners’ ability to successfully commercialize our products;

•the availability and scope of coverage and reimbursement for our products;

•the complexity and difficulty of manufacturing our products and product candidates;

•the substantial competition in our industry, including new technologies and therapies;

•the timing and results of any early research projects and future clinical outcomes;

•our reliance on third parties for preclinical studies and clinical trials and for the manufacture, production, storage and distribution of our products and product candidates and certain commercialization activities for our products;

•our ability to obtain, maintain and protect our intellectual property rights and our ability to operate our business without infringing on the intellectual property rights of others;

•our estimates regarding future revenue, expenses, liquidity, capital resources and needs for additional financing;

•the size and growth potential of the markets for our products and product candidates potential product liability lawsuits and product recalls;

•our ability to identify and successfully enter into strategic collaborations for research or licensing opportunities in the future;

•and those identified in the “Item 1A. Risk Factors” section contained in this Quarterly Report and our Annual Report on Form 10-K, and in our other reports filed with the U.S. Securities and Exchange Commission (the “SEC”), from time to time thereafter.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements, whether as a result of any new information, future events, changed circumstances or otherwise.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.

1.Description of Business and Organization

ADC Therapeutics is a leading, commercial-stage global pioneer in the field of antibody drug conjugates (“ADCs”) committed to advancing its proprietary ADC technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

Since its inception, the Company has devoted its resources to developing a validated and differentiated technology platform with multiple payloads and targets, a robust next-generation research and development toolbox, and specialized end-to-end capabilities. The Company generates sales from its flagship product, ZYNLONTA, which is currently approved in the U.S. for the treatment of relapsed or refractory diffuse large B-cell lymphoma (“DLBCL”) in the third-line setting and has also been granted conditional marketing authorization in Europe. Additionally, the Company is seeking to expand ZYNLONTA into earlier lines of therapy and indolent lymphomas, and is committed to advancing its portfolio and pipeline through its continued research, development, regulatory and commercialization activities.

The Company was incorporated on June 6, 2011 under the laws of Switzerland, with its registered office located at Route de la Corniche 3B, 1066 Epalinges, Switzerland. The Company has three wholly-owned subsidiaries: ADC Therapeutics America, Inc. (“ADCT America”), which was incorporated in Delaware, USA on December 10, 2014, ADC Therapeutics (UK) Ltd (“ADCT UK”), which was incorporated in England on December 12, 2014 and ADC Therapeutics (NL) B.V. which was incorporated in the Netherlands on February 25, 2022. The Company and its three subsidiaries form the ADCT Group (the “Group”).

All references to “ADC Therapeutics,” “the Company", “we,” “us,” and “our” refer to ADC Therapeutics SA and its unaudited condensed consolidated subsidiaries unless otherwise indicated.

2.Summary of Significant Accounting Policies

These accompanying unaudited condensed consolidated financial statements, which include the accounts of the Company and its wholly-owned subsidiaries, have been prepared following the requirements of the U.S. Securities and Exchange Commission for interim reporting. As permitted under those rules, certain footnotes and other financial information that are normally required by U.S. generally accepted accounting principles, or U.S. GAAP, can be condensed or omitted. All intercompany transactions and balances have been eliminated in consolidation. The information included in this Quarterly Report on Form 10‑Q should be read in conjunction with our annual audited consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10‑K for the year ended December 31, 2023.

In the opinion of management, these condensed consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements and include all adjustments, consisting only of normal recurring adjustments, considered necessary for the fair statement of our financial position and operating results. The results for the three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024, for any other interim period or for any future period.

The Company’s significant accounting policies have not changed substantially from those previously described in the Company’s Annual Report on Form 10‑K for the year ended December 31, 2023.

The Company is managed and operated as one business segment, focused on the global development and commercialization of targeted ADC cancer therapies. A single management team that reports to the chief operating decision-maker, the Chief Executive Officer, comprehensively manages and allocates resources at the global corporate level. Accordingly, the Company views its business and manages its operations as a single operating segment.

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the unaudited condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances.

Actual results could differ materially from those estimates.

We are responsible for evaluating, and providing disclosure of uncertainties about, our ability to continue as a going concern. As of September 30, 2024, we had cash and cash equivalents of $274.3 million. Based on our evaluation, we concluded there is no substantial doubt about our ability to continue as a going concern within one year from the date the unaudited condensed consolidated financial statements were issued.

There are no accounting pronouncements that the Company has recently adopted.

In November 2023, the FASB amended guidance in ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The revised guidance requires that a public entity disclose significant segment expenses regularly reviewed by the chief operating decision maker (CODM), including public entities with a single reportable segment. The amended guidance is effective for fiscal years beginning in January 2024 and interim periods beginning January 2025 on a retrospective basis. Early adoption is permitted. The Company is currently evaluating the effect that adoption of ASU 2023-07 will have on its consolidated financial statements.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The ASU requires the annual financial statements to include consistent categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Company’s annual reporting periods beginning in January 2025. Adoption is either with a prospective method or a fully retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the effect that adoption of ASU 2023-09 will have on its consolidated financial statements.

3.Fair value measurements

The carrying amount of Cash and cash equivalents, Accounts receivable, net and Accounts payable is a reasonable approximation of fair value due to the short-term nature of these assets and liabilities. Financial liabilities that are not measured at fair value on a recurring basis include our senior secured term loan. The estimated fair value of debt is based on Level 2 inputs, including our understanding of current market rates we could obtain for similar loans. 

The Deerfield warrants, which are measured at fair value on a recurring basis, were as follows as of September 30, 2024 and December 31, 2023:

Fair values must be estimated at the end of each reporting period with regard to the Deerfield warrants. The approach to valuation follows the fair value principle, and the key input factors are described for the Deerfield warrants in note 11, "Deerfield warrants." A Black-Scholes model was used to calculate the fair values.

There were no transfers between the respective levels during the period.

4.Inventory

As of September 30, 2024 and December 31, 2023 inventory consisted of the following:

Inventory write-downs of nil and $1,036 were recognized for the three and nine months ended September 30, 2024, respectively, and nil and $780 were recognized for the three and nine months ended September 30, 2023, respectively, and charged to cost of product sales in the Company’s unaudited condensed consolidated statements of operations.

5.Property and equipment

Property and equipment as of September 30, 2024 and December 31, 2023 consisted of the following:

Depreciation expense was $336 and $993 for the three and nine months ended September 30, 2024, respectively, and $316 and $852 for the three and nine months ended September 30, 2023, respectively.

6.Leases

The Company leases space for its corporate offices and research and development facilities under non-cancellable operating leases.

During the quarter ended September 30, 2024, the Company modified the terms of its existing lease for its office in New Jersey, USA. The existing lease contract was scheduled to expire on November 30, 2024, including an extension option for three additional years, which at inception, the Company believed was reasonably likely to be exercised. The Company extended the term by seven months commencing on December 1, 2024 and removed the three-year extension option.

Accordingly, the Company remeasured its lease liability and adjusted its right-of-use asset based on the revised lease term.

7.Interest in joint venture

On December 14, 2020, the Company formed a joint venture company, Overland ADCT BioPharma, with Overland Pharmaceuticals (“Overland”) to develop and commercialize ZYNLONTA, and three of the Company’s ADC product candidates, ADCT-601, ADCT-602 and ADCT-901 (collectively, the “Licensed Products”), in greater China and Singapore (the “Territory”).

The table below provides a rollforward of the Company’s interest in Overland ADCT BioPharma as of September 30, 2024 and December 31, 2023.

The Company recognized the proportionate share of Overland ADCT BioPharma’s net loss up to the investment carrying amount. The equity method investment in Overland ADCT Biopharma was reduced to zero during the three months ended September 30, 2024 and no further losses will be recorded in the Company's unaudited condensed consolidated financial statements as the Company has not incurred legal or constructive obligations or committed to additional funding on behalf of the joint venture. The Company will begin recognizing its share of net income only when it is greater than the cumulative net losses not recognized during the period the equity method was suspended.

8.Income taxes

Income tax expense for the three and nine months ended September 30, 2024 was $0.1 million and $0.5 million, respectively, relative to loss before income taxes of $43.6 million and $125.1 million, respectively. The income tax benefit for the three and nine months ended September 30, 2023 was $0.1 million and $4.1 million, respectively, relative to loss before income taxes of $45.4 million and $155.5 million, respectively. The expense for the three and nine months ended September 30, 2024 is the result of income generated by our UK operations for which tax expense has been recognized based on a full year estimated income tax liability, and the inability to recognize benefit on losses in the U.S. and Switzerland. Whereas the benefit for the three and nine months ended September 30, 2023 was the result of income generated in the U.S. and UK and a provision to return adjustment from prior year. The decrease in income for the U.S. operations is due to a change in the Company operating and transfer pricing model which was implemented in October 2023. We retain a full valuation allowance against all deferred tax assets, and each reporting period, we evaluate the need for a valuation allowance on our deferred tax assets by jurisdiction and adjust our estimates as more information becomes available.

9.Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consist of the following:

10.Senior secured term loan facility

On August 15, 2022, the Company, ADCT UK and ADCT America entered into the Loan Agreement, pursuant to which the Company may borrow up to $175.0 million principal amount of secured term loans, including (i) a First Tranche and (ii) Future Tranches. On August 15, 2022, the Company drew down $120.0 million principal amount of term loans under the Loan Agreement.

On August 15, 2022, the Company also issued to the lenders under the Loan Agreement warrants to purchase an aggregate of 527,295 common shares, which warrants have an exercise price of $8.30 per share. Each warrant is exercisable, on a cash or a cashless basis, at the option of the holder at any time on or prior to August 15, 2032. The warrants are freestanding financial instruments that are indexed to the Company’s common stock and meet all other conditions for equity classification under ASC 480 and ASC 815. Accordingly, these warrants are recognized in equity and accounted for as a component of additional paid-in capital at the time of issuance.

On August 15, 2022, the Company also entered into the Share Purchase Agreement with the lenders under the Loan Agreement to purchase 733,568 common shares of the Company.

For the three and nine months ended September 30, 2024, the Company recorded interest expense on the senior secured term loan in the amount of $4,585 and $13,401, respectively, and $4,728 and $13,748 for the three and nine months ended September 30, 2023, respectively, which was recorded in interest expense in the unaudited condensed consolidated statements of operations. The effective interest rate (“EIR”) at September 30, 2024 was 16.34%.

The following table provides a summary of the interest expense for the Company’s senior secured term loan for the three months ended September 30, 2024 and 2023:

The amount at which the senior secured term loan is presented as a liability in the unaudited condensed consolidated balance sheets represents the net present value of all future cash outflows associated with the loan discounted at the EIR. The carrying value of the senior secured term loan is $114.2 million and $112.7 million as of September 30, 2024 and December 31, 2023, respectively.

Contractual payments due under our senior secured term loans, including exit fees are as follows (in thousands):

11.Deerfield warrants

Pursuant to the Exchange Agreement with Deerfield entered into on August 15, 2022, the Company issued warrants to purchase an aggregate of 4,412,840 common shares. The warrants consist of warrants to purchase an aggregate of 2,631,578 common shares at an exercise price of $24.70 per share and warrants to purchase an aggregate of 1,781,262 common shares at an exercise price of $28.07 per share. Each warrant is exercisable, on a cash or a cashless basis, at the option of the holder, at any time on or prior to May 19, 2025. The warrant obligation, which is included in other long-term liabilities in the unaudited condensed consolidated balance sheets, is remeasured to fair value at the end of each reporting period. Changes in the fair value (gains or losses) of the warrant obligation at the end of each period are recorded in the unaudited condensed consolidated statements of operations.

During the three and nine months ended September 30, 2024, the Company recognized income of $1,130 and $292, respectively, and $140 and $776 for the three and nine months ended September 30, 2023, respectively, as a result of changes in the fair value of the warrant obligation. The fair value of the warrant obligation as of September 30, 2024 and December 31, 2023 was $4 and $296, respectively. The decrease in fair value of the warrant obligation from December 31, 2023 to September 30, 2024 was primarily due to decreases in the expected volatility partially offset by an increase in fair value of the underlying shares during the respective period. This amount was recorded to Other, net in the unaudited condensed consolidated statements of operations. See note 17, "Other income (expense)" for further information.

The Company valued the Deerfield warrant obligation using a Black-Scholes option-pricing model. Key inputs for the valuation of the warrant obligation as of September 30, 2024 and December 31, 2023 were as follows:

12.Deferred royalty obligation

On August 25, 2021, the Company entered into a royalty purchase agreement with certain entities managed by HCR for up to $325.0 million. Under the terms of the agreement, the Company received gross proceeds of $225.0 million upon closing (the “First Investment Amount”) and received an additional $75.0 million during the year ended December 31, 2023 upon the first commercial sale of ZYNLONTA in the United Kingdom or any European Union country (the “Second Investment Amount”) and together with the First Investment Amount, the “Investment Amount”).

The table below provides a rollforward of the Company’s debt obligation relating to the royalty purchase agreement.

13.Pension and post-retirement benefit obligations

The pension plan for Swiss employees is a defined benefit pension plan. The Company contracted with the Swiss Life Collective BVG Foundation based in Zurich for the provision of occupational benefits. All benefits in accordance with the regulations are reinsured in their entirety with Swiss Life SA within the framework of the corresponding contract. This pension solution fully reinsures the risks of disability, death and longevity with Swiss Life. Swiss Life invests the vested pension capital and provides a 100% capital and interest guarantee. The pension plan is entitled to an annual bonus from Swiss Life comprising the effective savings, risk and cost results.

Although, as is the case with many Swiss pension plans, the amount of ultimate pension benefit is not defined, certain legal obligations of the plan create constructive obligations on the employer to pay further contributions to fund an eventual deficit; this results in the plan nevertheless being accounted for as a defined benefit plan.

The net periodic benefit cost for the three and nine months ended September 30, 2024 and 2023 is as follows:

The components of net periodic benefit cost are included in operating expense on the unaudited condensed consolidated statements of operations.

14.Commitments and contingencies

Some of our inventory components require long lead times to manufacture. Therefore, we make long-term investments in our supply chain in order to ensure we have enough drug product to meet current and future revenue forecasts. Third party manufacturing agreements include non-cancelable obligations related to the supply of ZYNLONTA and the company’s product candidates. There have been no material changes related to our non-cancelable obligations under these arrangements as disclosed in our Annual Report on Form 10-K for the year ended December 31, 2023.

From time to time, we may be involved in various legal matters generally incidental to our business. Although the results of litigation and claims cannot be predicted with certainty, after discussion with legal counsel, we are not aware of any matters for which the likelihood of a loss is probable and reasonably estimable and which could have a material impact on our unaudited condensed consolidated financial condition, liquidity, or results of operation.

15.Shareholders’ equity

In May 2024, the Company completed an underwritten offering of equity securities in which 13,411,912 of the Company’s common shares were sold to public investors at a price of $4.90 per share and pre-funded warrants (the “2024 Pre-Funded Warrants”) to purchase 8,163,265 of the Company’s common shares were sold to public investors at a price of $4.81 per pre-funded warrant, which equals the per share 2024 Equity Offering price, less the CHF 0.08 exercise price for each pre-funded warrant (collectively, the “2024 Equity Offering”). Gross proceeds from the 2024 Equity Offering were approximately $105.0 million, and, after giving effect to $7.6 million of transaction costs related to the offering, net proceeds were approximately $97.4 million.

The 2024 Pre-Funded Warrants are exercisable, on a cash basis (or, if there is no registration statement and current prospectus covering the issuance of the shares upon exercise, then on a cashless basis), at the option of the holder after the date of issuance until the tenth anniversary of their original issuance. At any time during the last 90 days of the term, the holder may exchange the Pre-Funded Warrant for, and we will issue, a new pre-funded warrant for the number of common shares then remaining under the Pre-Funded Warrant. The Pre-Funded Warrants have certain limitations on exercise, including (i) any exercise must be for at least 50,000 common shares (or, if less, the remaining common shares available for purchase under the Pre-Funded Warrants), (ii) a holder cannot exercise for any amount that would cause such holder’s beneficial ownership of our common shares to exceed 9.99% (or 19.99% with 61-days’ notice to us), and (iii) cashless exercise is not available in certain circumstances as specified in the Pre-Funded Warrants. The warrants contain customary anti-dilution adjustments and will entitle holders to receive any dividends or other distributions paid on the underlying common shares prior to their expiration on an as-exercised basis.

The Company has accounted for the common shares and 2024 Pre-funded Warrants described above each as freestanding financial instruments.

The common shares were issued from the Company’s share capital and treasury shares at par value. The common shares were recorded as $60.5 million to equity for the issuance of the common shares, net of transaction costs accrued and paid, and an increase in cash and cash equivalents.

The warrants are freestanding financial instruments that are indexed to the Company’s common stock and meet all other conditions for equity classification under ASC 480 and ASC 815, including the warrant holders cannot require “net cash settlement” in a circumstance outside of the Company’s control, and there is sufficient authorized and unissued shares to settle the warrants. Accordingly, these warrants are recognized as $36.9 million in equity and accounted for as a component of additional paid-in capital at the time of issuance, net of transaction costs paid, and an increase in cash and cash equivalents.

Transaction costs have been allocated to the warrants and the common shares based on the relative fair value method. Transaction costs associated to the warrants and common shares have been deducted from the respective instrument in equity.

In August 2024, we filed a prospectus relating to an at-the-market offering program, pursuant to which we may offer and sell our common shares from time to time with an aggregate offering price of $100 million through Jefferies LLC acting as sales agent. For the three months ended September 30, 2024, we did not sell any shares under the program.

16.Revenue

The table below provides a disaggregation of revenues by type and customer location for the three and nine months ended September 30, 2024 and 2023:

(1) Europe, the Middle East and Africa

The table below provides a rollforward of the Company’s accruals related to the gross-to-net (“GTN”) sales adjustments for the three and nine months ended September 30, 2024:

The table below provides a rollforward of the Company’s accruals related to the GTN sales adjustments for the three and nine months ended September 30, 2023:

The table below provides the classification of the accruals related to the GTN sales adjustment included in the Company’s unaudited condensed consolidated balance sheets as of September 30, 2024 and December 31, 2023.